⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12368072 | 1.00 | — | — | |
| SCHEMBL16656709 | 1.00 | — | — | |
| SCHEMBL18122824 | 0.81 | — | — | |
| SCHEMBL1263633 | 0.81 | — | — | |
| SCHEMBL3669192 | 0.81 | — | — | |
| SCHEMBL16773934 | 0.80 | TGFBR1 (0.37) | — | |
| SCHEMBL24233166 | 0.79 | — | — | |
| Hydrochloric Acid SCHEMBL4812961 | 0.79 | — | — | |
| SCHEMBL8252892 | 0.79 | — | — | |
| SCHEMBL163350 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067702-A1 | LACTAM-MODIFIED POLYPEPTIDE COMPOUNDS | TONGHUA DONGBAO PHARMACEUTICAL CO., LTD. (CN) | 2024-02-29 | — | — | US | disclosed |
| WO-2017141032-A1 | TREATMENT OF FIBROTIC DISORDERS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2017-08-24 | — | — | WO | disclosed |
| US-20160215093-A1 | STABLE HELICAL IONIC POLYPEPTIDES | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2016-07-28 | — | — | US | disclosed |
| US-20160108098-A1 | THERAPEUTIC PEPTIDES | GLAXOSMITHKLLNE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-04-21 | — | — | US | disclosed |
| US-9243040-B2 | Stable helical ionic polypeptides | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2016-01-26 | — | — | US | disclosed |
| US-20150374843-A1 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | BRACCO INTERNATIONAL B.V. (NL) | 2015-12-31 | — | — | US | disclosed |
| US-9138470-B2 | Multi-component L2 vaccine for prevention of human papilloma virus infection | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-09-22 | — | — | US | disclosed |
| US-9090658-B2 | Base-substituted benzylamine analogs for use as coagulation factor Xa inhibitors, the production and use thereof | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2015-07-28 | — | — | US | disclosed |
| US-9090658-B2 | Base-substituted benzylamine analogs for use as coagulation factor Xa inhibitors, the production and use thereof | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2015-07-28 | — | — | US | disclosed |
| EP-2416801-B1 | IMMUNOGENIC COMPOSITION COMPRISING A TLR LIGAND AND AN ANTIGEN | UNIV MELBOURNE (AU) | 2015-07-22 | — | — | EP | disclosed |
| WO-2007139589-A1 | SUSTAINED RELEASE GLP-1 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-06 | — | — | WO | disclosed |
| US-20070253971-A1 | Immunogenic composition of vector; diagnostic immunoassays, probes and primers; host cells, genetic vaccines; administering to pregnant pigs | WYETH | 2007-11-01 | — | — | US | disclosed |
| US-20070243569-A1 | Protein kinase-inducible domains | DELAWARE, UNIVERSITY OF | 2007-10-18 | — | — | US | disclosed |
| US-20070243139-A1 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | BRACCO INTERNATIONAL B.V. (NL) | 2007-10-18 | — | — | US | disclosed |
| US-7261876-B2 | Multivalent constructs for therapeutic and diagnostic applications | BRACCO INTERNATIONAL BV (NL) | 2007-08-28 | — | — | US | disclosed |
| US-20070172428-A1 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | BRACCO INTERNATIONAL B.V. (NL) | 2007-07-26 | — | — | US | disclosed |
| US-20070066539-A1 | Base-substituted benzylamine analogs for use as coagulation factor xa inhibitors, the production and use thereof | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2007-03-22 | — | — | US | disclosed |
| US-20070066539-A1 | Base-substituted benzylamine analogs for use as coagulation factor xa inhibitors, the production and use thereof | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2007-03-22 | — | — | US | disclosed |
| WO-2005026198-A1 | BASE-SUBSTITUTED BENZYLAMINE ANALOGS FOR USE AS COAGULATION FACTOR XA INHIBITORS, THE PRODUCTION AND USE THEREOF | CURACYTE CHEMISTRY GMBH (DE) | 2005-03-24 | — | — | WO | disclosed |
| WO-2004094461-A2 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-11-04 | — | — | WO | disclosed |